Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 29 clinical trials
The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm

This trial aimed to investigate the therapeutic efficacy of ruxolitinib in combination with cytotoxic chemotherapy for post-myeloproliferative neoplasm secondary acute myeloid leukemia.

  • 1 views
  • 04 Mar, 2022
  • 2 locations
A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients 60 Years Old

biology (secondary AML, therapy related AML). Patients with a low risk of relapse will be allocated to consolidation, with three courses of high doses of Ara-C (HiDAC), or two courses of HiDAC with

secondary acute myeloid leukemia
myelodysplastic syndromes
acute promyelocytic leukemia
decitabine
remission
  • 32 views
  • 07 Oct, 2021
  • 10 locations
Uproleselan Cladribine and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia

This phase Ib/II trial finds out the best dose and effect of cladribine and low dose cytarabine when given in combination with uproleselan in treating patients with treated secondary acute

  • 0 views
  • 05 Jul, 2021
  • 1 location
Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML

This research is being done to assess the therapeutic efficacy and safety of a promising regimen (Venetoclax combined with Azacitidine and Harringtonine) in patients with secondary AML This study involves the following: Venetoclax combined with Azacitidine and Harringtonine

  • 0 views
  • 04 Oct, 2022
  • 1 location
CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML

The purpose of the study is to determine the safety of an investigational treatment for myelodysplastic syndrome (MDS) after the first therapy (such as azacitidine or decitabine) stops working or after progression of MDS to acute myeloid leukemia (AML). Funding source - FDA OOPD.

acute leukemia
secondary acute myeloid leukemia
anemia
hydroxyurea
acute promyelocytic leukemia
  • 0 views
  • 25 Mar, 2022
  • 1 location
Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm (CPX-351 TA-SMP)

-myelodysplastic syndrome (MDS) and post-MPN secondary AML in terms of disease resistance to chemotherapy, of fragile patient profile, The hypotheses made is that CPX-351 may improve the results of induction

direct bilirubin
gilbert's syndrome
anthracyclines
blast cells
cytarabine
  • 0 views
  • 04 Oct, 2022
  • 20 locations
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old

secondary acute myeloid leukemia
daunorubicin
myeloid leukemia
chronic myelomonocytic leukemia
cytarabine
  • 0 views
  • 23 May, 2022
  • 3 locations
A Study of CG-806 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

This study is being done to evaluate the safety, tolerability and antitumor activity of oral CG-806 for the treatment of patients with Acute Myeloid Leukemia (except APML), secondary AML, or

refractory acute myeloid leukemia (aml)
secondary acute myeloid leukemia
acute promyelocytic leukemia
  • 0 views
  • 30 Jul, 2021
  • 9 locations
Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia

This is a prospective phase II clinical study to be conducted at the Medical College of Wisconsin. After meeting the study criteria and enrollment, patients will be treated with Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) chemotherapy and followed at periodic intervals to determine the primary and secondary objectives.

direct bilirubin
mitoxantrone
secondary acute myeloid leukemia
hemolysis
colony stimulating factor
  • 60 views
  • 01 May, 2022
  • 1 location
Dose-Reduced Versus Standard Conditioning Prior Allo SCT for MDS/sAML Patients

unrelated donors in patients with MDS or secondary AML. The hypothesis is that dose-reduced conditioning will reduce the non-relapse mortality from 40% to 20% at one year after allogeneic stem

busulfan
cyclophosphamide
fludarabine
cell transplantation
  • 28 views
  • 07 Nov, 2020
  • 1 location